Loading…
Loading…
RPTX (Repare Therapeutics Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Repare Therapeutics Inc. (NASDAQ: RPTX - Get Free Report)'s stock price rose 0.8% on Thursday. The company traded as high as $2.65 and last traded at $2.65. Approximately 1,219,900 shares were traded during trading, an increase of 29% from the average daily volume of 947,968 shares. The stock had previously closed at $2.63. Wall Street
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly “Xeno”) a non-profit biotechnology company, b.
Repare Therapeutics Inc. (NASDAQ: RPTX - Get Free Report)'s stock price rose 0.4% on Wednesday. The stock traded as high as $2.61 and last traded at $2.60. Approximately 426,036 shares changed hands during trading, a decline of 71% from the average daily volume of 1,465,188 shares. The stock had previously closed at $2.59. Analyst Upgrades
Repare Therapeutics Inc. (NASDAQ: RPTX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors acquired 3,187 call options on the company. This is an increase of approximately 407% compared to the typical daily volume of 629 call options. Institutional Trading of Repare Therapeutics A number of institutional investors have recently
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”). “We are pleased to announce this transaction which combines Gilead's leading expertise in oncology research and development with RP-3467, a potential best-in-class.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
BALA CYNWYD, Pa., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating